Article
Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma
7 Jan 2015
Abstract excerpt
UNLABELLED: In neuroblastoma, MYCN genomic amplification and segmental chromosomal alterations including 1p or 11q loss of heterozygocity and/or 17q gain are associated with progression and poor clinical outcome. Segmental alterations are the strongest predictor of relapse and result from unbalanced translocations attributable to erroneous repair of chromosomal breaks. Although sequence analysis of affected...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
